FMDV Consensus Protein Vaccine Broad Subtype Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against foot-and-mouth disease virus (FMDV) do not provide effective protection across multiple subtypes, requiring multiple inoculations and relying on expensive high-containment manufacturing facilities, and there is a need for a method to distinguish between vaccinated and infected individuals.
Innovation Solution
Development of a vaccine using a DNA plasmid encoding a consensus amino acid sequence of FMDV capsid proteins VP1-4, capable of eliciting an immune response against multiple FMDV subtypes, and a method to diagnose infection by comparing antibodies in vaccinated and infected individuals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically inactivated whole virus antigen is used in vaccine, then immune protection is provided, but expensive high-containment manufacturing facilities are required
Solution Approach 1:
The patent extracts the essential immunogenic components (capsid proteins VP1-4) from the complete virus structure. By using only the protective antigenic proteins rather than the whole inactivated virus, the vaccine achieves immune protection without requiring expensive high-containment manufacturing facilities for virus cultivation and inactivation.
Solution Approach 2:
The patent creates a simplified copy of the virus's immunogenic essence through consensus protein sequences that represent multiple FMDV subtypes. This synthetic consensus protein copy captures the essential protective antigens while eliminating the need for complex virus handling and manufacturing infrastructure.
2Ease of manufacture
If VP1 purified from virus particles or VP1 peptides are used, then vaccine development is simplified, but only a limited number of epitopes across FMDV subtypes are presented
Solution Approach 1:
The patent creates a universal vaccine antigen by constructing consensus protein sequences that incorporate conserved epitopic regions from multiple FMDV subtypes (A, Asia 1, C, O, SAT1, SAT2, SAT3). This single consensus protein formulation provides broad cross-protection across all major FMDV subtypes, eliminating the need for subtype-specific vaccines while maintaining manufacturing simplicity.
Solution Approach 2:
The consensus protein is constructed as a composite sequence that integrates conserved antigenic determinants from multiple viral subtypes. By combining protective epitopes from different FMDV strains into a single consensus sequence, the vaccine achieves broad-spectrum immunity while maintaining the simplicity of peptide-based production.
3Productivity
If countries use vaccination to treat FMDV outbreak, then animal slaughter is avoided, but FMD free status cannot be regained for one year
Solution Approach 1:
The patent enables preliminary vaccination with consensus proteins that provide broad cross-protection before outbreaks occur. By pre-immunizing livestock with a single inoculation of the multi-subtype consensus vaccine, countries can maintain FMD-free status while having animals already protected against emerging strains, eliminating the need to sacrifice productivity during outbreaks.
4Adaptability or versatility
If multiple subtypes of FMDV vaccines are developed, then protection against various subtypes is achieved, but device and vaccine complexity increases
Solution Approach 1:
The patent merges the protective antigens from multiple FMDV subtypes into a single consensus protein formulation. By combining conserved epitopic sequences from subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 into one unified vaccine product, the patent achieves multi-subtype protection without requiring separate vaccines for each subtype, thereby simplifying rather than complicating the vaccine system.
Data Source
AI summary
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.